But it’s almost two years now that scientists are continuously looking for a drug that can treat people who are already sick. During this period a lot of treatments options were proposed that successfully passes the in-vitro studies but were failed during clinical trials. The available treatment options that are FDA approved are remdesivir and monoclonal antibodies. But both of these options are expensive and require hospital visits for intravenous administration. Roche’s Actemra/ RoActemra also get FDA authorization for emergency use for the treatment of COVID-19 in hospitalized patients. There was a continuous try to develop oral treatment options for the patients who are suffering from mild to moderate infection. In this race, antimalarial drug hydroxychloroquine and antiparasitic drug ivermectin were proposed as treatment options but these didn’t work. Then steroid dexamethasone was also proposed but this was for critically ill patients.